Laboratory of Psychobiology, Department of Psychiatry, Rambam Health Care Campus and B. Rappaport Faculty of Medicine, Rappaport Family Institute for Research in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel.
Laboratory of Psychobiology, Department of Psychiatry, Rambam Health Care Campus and B. Rappaport Faculty of Medicine, Rappaport Family Institute for Research in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel.
Biol Psychiatry. 2018 May 1;83(9):770-779. doi: 10.1016/j.biopsych.2017.08.007. Epub 2017 Aug 15.
The neurobiology of psychiatric disorders is still unclear, although changes in multiple neuronal systems, specifically the dopaminergic, glutamatergic, and gamma-aminobutyric acidergic systems as well as abnormalities in synaptic plasticity and neural connectivity, are currently suggested to underlie their pathophysiology. A growing body of evidence suggests multifaceted mitochondrial dysfunction in mental disorders, which is in line with their role in neuronal activity, growth, development, and plasticity. In this review, we describe the main endeavors toward development of treatments that will enhance mitochondrial function and their transition into clinical use in congenital mitochondrial diseases and chronic disorders such as types 1 and 2 diabetes, cardiovascular disorders, and cancer. In addition, we discuss the relevance of mitochondrial targeted treatments to mental disorders and their potential to become a novel therapeutic strategy that will improve the efficiency of the current treatments.
精神疾病的神经生物学机制仍不清楚，尽管目前认为多种神经元系统（特别是多巴胺能、谷氨酸能和γ-氨基丁酸能系统）的变化以及突触可塑性和神经连接的异常是其病理生理学的基础。越来越多的证据表明，精神疾病存在多方面的线粒体功能障碍，这与它们在神经元活动、生长、发育和可塑性中的作用一致。在这篇综述中，我们描述了主要的努力，以开发能够增强线粒体功能的治疗方法，并将其转化为先天性线粒体疾病和慢性疾病（如 1 型和 2 型糖尿病、心血管疾病和癌症）的临床应用。此外，我们还讨论了线粒体靶向治疗与精神疾病的相关性及其成为一种新的治疗策略的潜力，这种策略将提高现有治疗方法的效率。
